BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cutaneous T-Cell Lymphoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Cutaneous T-Cell Lymp
 homa\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05357794-2202@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05357794)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Th
 erapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients 
 With Mycosis Fungoides\nEstimated primary completion: 30 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05357794
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03587844-2202@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT03587844)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Dosing of Brentuximab Vedotin for Mycosis Fungoides\, Sezary Syndrome 
 Patients\nEstimated primary completion: July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03587844
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01352520-2202@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT01352520)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL)\, Mycosis
  Fungoides (MF)\, and Extensive Lymphomatoid Papulosis (LyP)\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT01352520
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717580-2202@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT07717580)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax i
 n CD30+ Cutaneous T-cell Lymphoma (CTCL)\nEstimated primary completion: 30
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brent
 uximab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07717580
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178457-2202@assetmemo.bio
DTSTAMP:20261121T005722Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT07178457)
DESCRIPTION:Brentuximab Vedotin\, phase 3\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogen
 eic Hematopoietic Stem Cell Transplant Maintenance\nEstimated primary comp
 letion: 1 November 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/brentuximab-vedotin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07178457
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
